Drug profile · INN
retifanlimab-dlwr
ZYNYZ
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
retifanlimab-dlwr (ZYNYZ) is an FDA-listed pharmaceutical active ingredient. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
INN retifanlimab-dlwr
Brand ZYNYZ
Route INTRAVENOUS
Formulation INJECTABLE
Frequently asked questions
What is retifanlimab-dlwr?
retifanlimab-dlwr (ZYNYZ) is an FDA-listed pharmaceutical active ingredient. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for retifanlimab-dlwr?
ZYNYZ is a marketed brand name for retifanlimab-dlwr. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of retifanlimab-dlwr?
retifanlimab-dlwr has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.